The Neurotech Platform for Mental Health at Scale

Invest now →

$11.21 / share$11.60 including 3.5% fee

SEC Filings | Form C | Investor Education

Minimum for Bonus Shares: $113 | Minimum for Free OAK Coupon: $1503

More than $16 million raised to date

The First Rapid-Acting Prescription Wearable

Wearable brain stimulation that rapidly treats insomnia, anxiety, and depression.

The result of 17 years of clinical research and product development, millions of hours of real-world testing, and a groundbreaking collaboration with the talent behind Beats and Nest.

7 studies, multiple published; collectively enrolled more than 1500 participants
60,000 active proof-of-concept device users (real world)
Stimulates brain structures that govern mood and sleep (the limbic-autonomic axis / midline brain)
Used 20 minutes, 1× or 2× per day
Proven effective starting Week 1 (significantly superior to placebo)

Our research devices are in use at the U.S. Department of Veterans Affairs. FDA clearance is expected within the next few months.

Problem

The world needs more than treatment: it needs preventative neural infrastructure.

Standards of care for anxiety, depression and insomnia intervene too late, and are often slow-acting, hard to adhere to, and/or cause side effects. The most effective wearable brain stimulation follows first principles: optimize for lifelong brain performance as the path to eliminating symptoms.

100M – 140MAmericans with clinical anxiety, depression, or insomnia symptoms (1.8–2.5B worldwide)

≈50%Of Americans with mood and sleep disorders go untreated in a year.

≈1.7MVeterans provided mental health treatment by the U.S. Dept. of Veterans Affairs annually, at a cost of ≈$20B

Regulatory Paths

A treatment platform with paths to three FDA indications in 2026 and 2027.

FDA Clearance · Anxiety

Application submitted to FDA

Study achieved primary endpoint and is pending publication
Regulatory consulting team includes former FDA staff
Clearance expected in 2026 (Q4)

FDA Approval · Depression in Women

Application on track for submission in Q1 2027

Study published in the Journal of Clinical Psychiatry
Active treatment significantly superior to placebo (sham) among the 185 female participants at every time point

FDA Clearance · Insomnia

Application planned for 2027

Pilot study demonstrates rapid and significant increase in total sleep time versus placebo
Pivotal study in pipeline

⏰

This equity crowdfunding campaign ends soon. Invest $113+ to receive 100% bonus shares. Example: if you purchase 100 shares, you will receive a total of 200 shares.

Invest $1,503+ and receive 100% bonus shares AND a coupon code for a free OAK (a prescription will still be required in the US).

How It Works

OAK harnesses, not inhibits, the brain.

Electric-field modeling by researchers at Massachusetts General Hospital and Harvard Medical School demonstrates how OAK significantly engages the anterior cingulate cortex, amygdala, hippocampus, insula, thalamus, and upper brainstem — the structures that govern mood, sleep, and cognitive resilience.

Electric-field modeling of OAK stimulation in the brain

Completed Clinical Research

A single device, validated to treat three of the world's most common health conditions.

Treatment of Anxiety

164 active first responders · 8 weeks

Conducted in partnership with the Seattle Police Department. Rapid, durable efficacy with no serious adverse events. Submitted to the FDA for clearance in 2026.

Depression in Women

185 women · 4 weeks

Rapid efficacy beginning in Week 1 with no serious adverse events. Preparing for FDA approval submission.

Treatment of Insomnia

48 subjects w/ complete sleep data · 4 weeks

Active-treatment produced 42 more minutes of sleep (TST) per night than placebo.

Research Partners

U.S. Dept. of Veterans Affairs Massachusetts General Hospital Harvard Medical School Mount Sinai Beth Israel Hospital Seattle Police Department Phoenix House Team Liquid (via Sapere)

Design & Engineering

We collaborated with the dream team behind Beats, Nest, and HoloLens to turn medtech into culture:

Eric Fields

Industrial Designer

Red Dot Award (×2) · Nest Thermostat · Beats Pill

Chris Fruhauf

Lead Engineer

Beats · HoloLens

Product-Market-Fit

60,000 active users and 14,000 prescribers of our proof-of-concept device.

Before the FDA finalized the category’s regulation in 2019, it allowed us to commercialize our proof-of-concept device. We used that opportunity to establish real-world dosing and treatment protocols, navigate Medicaid reimbursement, build our manufacturing and quality systems, and educate thousands of healthcare providers. Early-adopter traction allowed us to operate and conduct R&D for 10 years without raising any outside capital.

“I have had great success using the device to treat severe, chronic insomnia in patients who are resistant to pharmacotherapy.”

— Andres San Martin, MD, PhD · Assistant Clinical Professor of Psychiatry, Columbia University

Go-to-Market

Government procurement is the economic bridge to commercial reimbursement.

Maclean Health selected as VA and DoD sales and distribution partner.

Additional sales channels

Telemedicine-powered eCommerce
Self-Funded Employer Health Plans
Private Practices
Outpatient & Inpatient Facilities
Version 1.0 User Upgrades
Consumer Health Platforms
Medicaid & Medicare Programs

Advisors

Guided by leaders in psychiatry and veteran health.

Dr. Maurizio Fava

Advisor

Psychiatrist-in-Chief, Massachusetts General Hospital · Associate Dean of Clinical Research, Harvard Medical School.

Dr. David Shulkin

Advisor

Ninth U.S. Secretary of Veterans Affairs · former CEO, Beth Israel Medical Center.

Dr. Joan Camprodon

Advisor

Chief, Division of Neuropsychiatry, MGH · Associate Professor of Psychiatry & Neurology, Harvard Medical School.

Co-Founders

Pioneering the wearable brain stimulation category for 17 years.

Kelly Roman

Co-Founder & CEO

Son of a U.S. Army veteran. Harvard College (1996). Former Nielsen; published author (HarperCollins).

Charles “Chip” Fisher

Co-Founder & Chairman

Son of audio pioneer Avery Fisher. Harvard College (1978). Former IBM; investor and philanthropist.

Join the mission

Own part of the company reinventing mental health care.

★Invest $113+ → receive 100% bonus shares (for example: buy 100 shares and receive 100 bonus shares for a total of 200 shares).

★Invest $1,502.90+ → receive 100% bonus shares AND a coupon code for a free OAK (Rx still required).

Invest now →

Takes about 2 minutes · Secured by DealMaker Securities LLC · Encrypted & confidential

FAQ · Investor education

Questions investors ask.

Why invest in startups? +

Regulation CF allows investing in startups and early-growth companies. Unlike Kickstarter, you aren't buying products or merchandise — you are buying a piece of a company and helping it grow.

How much can I invest? +

Accredited investors can invest any amount. Non-accredited investors' limits depend on annual income or net worth (whichever is greater). Below $124,000, you can invest the greater of $2,500 or 5%; above that threshold, up to 10% (capped at $124,000 annually).

How do Bonus Shares work? +

Investors who invest $113 or more receive 100% Bonus Shares, doubling the number of shares purchased at no additional cost. For example, an investment that purchases 100 shares receives an additional 100 Bonus Shares, for 200 total shares.

What is Fisher Wallace Labs' pre-money valuation? +

Fisher Wallace Labs' pre-money valuation is $120,500,000. It was calculated by multiplying the total number of shares outstanding by the price per share offered in this raise — the company's value before new funds are added.

How do I calculate my net worth? +

Add up all of your assets and subtract all of your liabilities (excluding the value of your primary residence).

What are the tax implications of an equity crowdfunding investment? +

Tax advice cannot be provided. Please consult an accountant or tax advisor before investing.

Who can invest in a Regulation CF offering? +

Individuals over 18 years of age can invest.

What risks are involved? +

There will always be some risk involved when investing in a startup or small business. Company failure could mean a total loss; shares may lack voting rights; and exits typically require 5–10 years.

Is Fisher Wallace Laboratories stock publicly traded? +

The Common Stock of Fisher Wallace Laboratories is not publicly traded. Shares cannot be easily traded; returns depend on an acquisition or IPO, typically after 5–10 years.

What are exceptions to the one-year lockup period restrictions? +

In cases of death, divorce, or similar circumstances, shares may transfer to: the company that issued the securities, accredited investors, or specified family members.

What happens if the funding target isn't reached? +

If a company does not reach its minimum funding target, all funds will be returned to investors after the close of the offering.

How can I learn more about the offering? +

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering, and in the SEC Form C.

What if I change my mind about investing? +

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. Funds in escrow are promptly refunded upon cancellation.

How do I keep up with company progress? +

At a minimum, the company will file with the SEC and post on its website an annual report, along with certified financial statements, within 120 days of its fiscal year end.

What relationship does the company have with DealMaker Securities? +

The company may continue its relationship with DealMaker Securities for additional offerings, with no guarantee that services will continue after this offering ends.

Discussion

Investor questions & comments

Have a question about the raise? Post it below. Comments are public and reviewed by our team before they appear.